论文部分内容阅读
目的评价稳心颗粒联合比索洛尔治疗冠心病心律失常的疗效和安全性。方法计算机检索Pubmed、Cochrane Library、Embase、维普数据库(VIP)、万方数据库及中国知网中关于稳心颗粒联合比索洛尔治疗冠心病心律失常的随机对照试验(RCTs),对纳入的研究判断其偏倚风险,对文献数据使用Rev Man 5.3进行Meta分析。结果共检索文献339篇,经筛选后纳入7个RCTs,共涉及683例患者。Meta分析结果显示:对冠心病心律失常患者的心律失常改善显效率[RR 1.33,95%CI(1.23,1.45),P<0.01]和心悸症状改善显效率[RR 1.26,95%CI(1.17,1.36),P<0.01],联合组(稳心颗粒+比索洛尔)优于对照组(比索洛尔);而对于药物不良反应发生率[RR 0.41,95%CI(0.22,0.77),P<0.01],联合组小于对照组。结论本文结果一定程度显示稳心颗粒联合比索洛尔在治疗冠心病心律失常方面疗效显著,可减少不良反应。
Objective To evaluate the efficacy and safety of Wenxin Granule combined with bisoprolol in the treatment of arrhythmia of coronary heart disease. Methods Randomized controlled trials (RCTs) of PubMed, Cochrane Library, Embase, VIP database, Wanfang database and China National Knowledge Network for the treatment of coronary heart disease with Wenxin granule combined with bisoprolol were searched. Risk of bias, Meta-analysis of literature data using Rev Man 5.3. Results A total of 339 articles were retrieved. After screening, 7 RCTs were involved, involving a total of 683 patients. Meta-analysis showed that the effective rate of arrhythmia was significantly improved in patients with coronary heart disease (RR 1.33, 95% CI 1.23, 1.45, P 0.01) and in patients with palpitation (RR 1.26, 95% CI 1.17, 1.36), P <0.01], combined group (Wenxinkeli + bisoprolol) was superior to the control group (bisoprolol); while the incidence of adverse drug reactions [RR 0.41,95% CI (0.22,0.77), P <0.01], the combined group is smaller than the control group. Conclusion The results of this study to a certain extent Wenxin particles combined with bisoprolol in the treatment of coronary heart disease arrhythmia significant effect, can reduce the adverse reactions.